| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net loss | ||||||||
-40,675 | -32,968 | -31,768 | -27,637 | -22,192 | -19,270 | 0 | 0 | 0 |
Reconciliation of net loss to net cash used in operating activities | ||||||||
Depreciation and amortization | ||||||||
166 | 156 | 0 | 0 | 0 | - | - | - | - |
Stock-based compensation expense | ||||||||
3,236 | 3,142 | 2,621 | 2,735 | 2,445 | 3,082 | 0 | 0 | 0 |
Due to Parent under asset contribution agreement | ||||||||
- | - | - | - | 0 | - | - | - | 0 |
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other assets | ||||||||
1,736 | 1,190 | 642 | 882 | 1,026 | 539 | 0 | 0 | 0 |
Accounts payable, accrued expenses and other | ||||||||
5,742 | 3,580 | 5,866 | 6,423 | 3,065 | 3,201 | 0 | 0 | 0 |
Due to related party | ||||||||
- | - | - | - | - | - | - | - | 0 |
Net cash used in operating activities | ||||||||
-33,767 | -27,280 | -23,697 | -19,224 | -18,167 | -13,509 | 0 | 0 | 0 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Purchases of equipment and leasehold improvements | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Net cash used in investing activities | ||||||||
-286 | -870 | 0 | 0 | 0 | - | - | - | - |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from issuance of common stock, net of issuance costs | ||||||||
0 | - | - | - | - | 56,513 | 0 | 0 | 0 |
Purchase and cancellation of shares from BioXcel Corporation | ||||||||
0 | - | - | - | - | - | - | - | - |
Exercise of options | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Due to Parent | ||||||||
- | - | - | - | - | -555 | 0 | 0 | 0 |
Note Payable — Parent | ||||||||
- | - | - | - | - | -371 | 0 | 0 | 0 |
Net cash provided by financing activities | ||||||||
77,836 | 18,011 | 17,853 | -115 | -62 | 55,527 | 0 | 0 | 0 |
Net (decrease) increase in cash and cash equivalents | ||||||||
43,783 | -10,139 | -6,870 | -20,384 | -19,169 | 41,678 | 0 | 0 | 0 |
Supplemental cash flow information: | ||||||||
Interest paid | ||||||||
57 | 62 | 47 | 29 | 7 | 1 | 0 | 0 | 0 |
Supplemental disclosure of non-cash Operating, Investing and Financing Activities: | ||||||||
Deferred issuance costs, unpaid as of December 31, 2017 | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |
Deferred issuance costs reclassified to additional paid-in-capital upon completion of initial public offering | ||||||||
- | - | - | - | - | 461 | 0 | 0 | 0 |
Reclassification of net Parent Investment in the Company to accumulated deficit. | ||||||||
- | - | - | - | - | - | 0 | 0 | 0 |